Post by tatshensini on Jun 3, 2016 17:49:53 GMT
Just took a position in Moleculin, MBRX.
Following their Annamyacin entering clinical phase two trials for AML
A RECENT BREAKTHROUGH
Celator VS Annamyacin www.moleculin.com/technology/annamycin/anna-vs-dauno-investors/
In the last year, many people in the AML field have been watching a company named Celator Pharmaceuticals (NASDAQ: CPXX).
Celator’s stock has greatly appreciated since the announcement of its Phase III clinical results and recently a large pharmaceutical company just announced its intention to acquire Celator for $1.5 billion.
All of this excitement has been the result of clinical findings demonstrating that by tweaking the delivery method of the existing “7+3 induction therapy”, for the 80% of patients that do not achieve a complete response, their expected lifespan will increase to 9.5 months versus a 6-month prognosis for the classical treatment.
Celator took the standard 7+3 formula and combined the two drugs into one liposomal formulation (at a 5:1 ratio). Administered in three IV injections over 5 days, patient lifespan was increased from 6 months to 9.5 months – an extra 3.5 months, an almost 50% increase in survival time. From a patient point of view, an extra 3.5 months of survival time is a gift.
If the FDA approves Vyxeos as a new first-line therapy, there is a good possibility that it could become the new standard of care for AML patients.
Based on the data available, this therapy does not appear to increase the rate of long-term survival for the unlucky 80%. It essentially extends life for them by an extra 3.5 months, but it doesn’t appear to increase their chances of qualifying for a bone marrow transplant. It also doesn’t appear to tackle the fundamental problems attributed with currently approved anthracyclines: cardiotoxicity and multi-drug resistance.
Celator Market Cap of 1.29 Billion
Moleculin MC 116 Million
COMPANY OVERVIEW
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company
focused on the development of anti-cancer drug candidates, many of which are
based on discoveries made at M.D. Anderson Cancer Center. Our lead product
candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of
relapsed or refractory acute myeloid leukemia, more commonly referred to as AML.
We also have two active pre-clinical small molecule portfolios, one of which is
focused on the modulation of hard-to-target tumor cell signaling mechanisms and
the recruitment of the patient's own immune system. The other portfolio targets
the metabolism of tumors.
RECENT NEWS
Moleculin Biotech, Inc. to Present at the 2016 Marcum MicroCap
Conference
Jun 2 2016, 10:00 AM EDT
Moleculin Biotech, Inc. Completes Initial Public Offering
Jun 2 2016, 9:56 AM EDT
Moleculin Biotech, Inc. Completes Initial Public Offering; MBRX Shares
Set to Commence Trading on NASDAQ Capital Market June 2, 2016
Jun 1 2016, 6:15 PM EDT
Symbol MBRX
Exchange NASDAQ
Shares OS 6,895,296
Market Cap $55.16M
Last Price $8.00
52-Week Range $7.61 - $9.49
vimeo.com/152752751
www.moleculin.com/
Following their Annamyacin entering clinical phase two trials for AML
A RECENT BREAKTHROUGH
Celator VS Annamyacin www.moleculin.com/technology/annamycin/anna-vs-dauno-investors/
In the last year, many people in the AML field have been watching a company named Celator Pharmaceuticals (NASDAQ: CPXX).
Celator’s stock has greatly appreciated since the announcement of its Phase III clinical results and recently a large pharmaceutical company just announced its intention to acquire Celator for $1.5 billion.
All of this excitement has been the result of clinical findings demonstrating that by tweaking the delivery method of the existing “7+3 induction therapy”, for the 80% of patients that do not achieve a complete response, their expected lifespan will increase to 9.5 months versus a 6-month prognosis for the classical treatment.
Celator took the standard 7+3 formula and combined the two drugs into one liposomal formulation (at a 5:1 ratio). Administered in three IV injections over 5 days, patient lifespan was increased from 6 months to 9.5 months – an extra 3.5 months, an almost 50% increase in survival time. From a patient point of view, an extra 3.5 months of survival time is a gift.
If the FDA approves Vyxeos as a new first-line therapy, there is a good possibility that it could become the new standard of care for AML patients.
Based on the data available, this therapy does not appear to increase the rate of long-term survival for the unlucky 80%. It essentially extends life for them by an extra 3.5 months, but it doesn’t appear to increase their chances of qualifying for a bone marrow transplant. It also doesn’t appear to tackle the fundamental problems attributed with currently approved anthracyclines: cardiotoxicity and multi-drug resistance.
Celator Market Cap of 1.29 Billion
Moleculin MC 116 Million
COMPANY OVERVIEW
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company
focused on the development of anti-cancer drug candidates, many of which are
based on discoveries made at M.D. Anderson Cancer Center. Our lead product
candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of
relapsed or refractory acute myeloid leukemia, more commonly referred to as AML.
We also have two active pre-clinical small molecule portfolios, one of which is
focused on the modulation of hard-to-target tumor cell signaling mechanisms and
the recruitment of the patient's own immune system. The other portfolio targets
the metabolism of tumors.
RECENT NEWS
Moleculin Biotech, Inc. to Present at the 2016 Marcum MicroCap
Conference
Jun 2 2016, 10:00 AM EDT
Moleculin Biotech, Inc. Completes Initial Public Offering
Jun 2 2016, 9:56 AM EDT
Moleculin Biotech, Inc. Completes Initial Public Offering; MBRX Shares
Set to Commence Trading on NASDAQ Capital Market June 2, 2016
Jun 1 2016, 6:15 PM EDT
Symbol MBRX
Exchange NASDAQ
Shares OS 6,895,296
Market Cap $55.16M
Last Price $8.00
52-Week Range $7.61 - $9.49
vimeo.com/152752751
www.moleculin.com/